Incidence of Human Leukocyte Antigen (HLA) Class I Antibodies and Impact on Platelet Engraftment, Transfusions and Bleeding in Recipients of Gene Therapy for Sickle Cell Disease and Transfusion Dependent Beta Thalassemia

Key Points

• Platelet engraftment rates were significantly affected by the presence of HLA class I antibodies, which contributed to increased transfusion needs.
• Among recipients of gene therapy for both sickle cell disease and beta thalassemia, bleeding complications were notably higher when HLA class I antibodies were present.
• The findings highlight an important relationship between HLA class I antibodies and transfusion outcomes, emphasizing the need for careful monitoring in gene therapy contexts.
• Future strategies in gene therapy may need to address HLA class I antibody management to improve patient outcomes and reduce bleeding risks.